Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: Fabrazyme
Active Ingredient: Agalsidase beta 5.5mg
Dosage Form: Powder for infusion concentrate
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Genzyme Corporation, Allston, Massachusetts, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 30th day of October 2009.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).